Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Non-randomized, Open Label Study to Evaluate the Efficacy and Security of Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03280160 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT03280160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03280160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Non-randomized, Open Label Study to Evaluate the Efficacy and Security of Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Unknown status
Start date
September 7, 2017
Completion date
September 30, 2022
Enrollment
84 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia